About

HiFiBiO Therapeutics is an emerging clinical stage multinational company mobilizing the human immune system to treat cancer and autoimmune disease.

Our Vision

Pioneering curative immunotherapies for each and every patient

Our Mission

Unlocking the curative powers of the immune system with innovative biotherapeutics

Our Strategy

HiFiBiO Therapeutics is harnessing its cutting-edge single cell technologies and an open innovation partnership model to develop a sustainable pipeline of innovative immunotherapies

Leadership Team

Liang Schweizer, PhD
Co-founder, Chairman, Chief Executive Officer
Francisco Adrian, PhD
Chief Scientific Officer
Luigi Manenti, MD
Chief Medical Officer
John Pallante
Vice President, Global Head of Clinical Operations
Christos Hatzis, PhD
Vice President, Global Head of Clinical Pharmacogenomics
Edward Rocnik, PhD
Executive Director, Global Head of CMC
Jinping Gan, PhD
Executive Director, Global Head of Antibody Discovery and Optimization (ADO)
Andreas Raue, PhD
Executive Director, Global Head of Drug Intelligent Science (DIS)
Rachel Yao
Financial Controller
Vincent Tse, MBA
Senior Director of Staff and Strategy
He Zhou, PhD
Vice President, China General Manager
Sami Ellouze
Director, France General Manager
Roshan Kumar, PhD
Senior Director, US External Innovation

Scientific Advisory Board

Michael Croft, PhD

Director of Scientific Affairs, Professor and Head of the Division of Immune Regulation at La Jolla Institute for Immunology                                                      

Leslie Kean, MD, PhD

Director of the Stem Cell Transplantation Program and Physician at Dana-Farber/Boston Children’s Cancer Center and Blood Disorders Center

Aurélien Marabelle, MD, PhD

Senior Medical Oncologist in the Drug Development Department and the Clinical Director of the Cancer Immunotherapy Program at Gustave Roussy

Vikas P. Sukhatme, MD, ScD

Dean of the Emory School of Medicine, Chief Academic Officer of Emory Healthcare and Woodruff Professor at the Emory School of Medicine

Sebastian Amigorena, PhD

Director of the INSERM Immunity and Cancer Lab, and head of the Immunology and Immunotherapy department at Institut Curie.

Scientific Founders

Andrew Griffiths, PhD

Professor of Biochemistry at École Supérieure de Chimie Industrielles de Paris (ESPCI) in Paris

David Weitz, PhD

Mallinckrodt Professor of Physics & Applied Physics and professor of Systems Biology at Harvard University

Bradley Bernstein, MD, PhD

Professor of Pathology at the Massachusetts General Hospital and Harvard Medical School

Jérôme Bibette, PhD

Professor of soft matter physics at École Supérieure de Chimie Industrielles de Paris (ESPCI)

Robert Nicol, PhD

Director of the Technology Labs at the Broad Institute of MIT and Harvard

Our Investors

We are funded by leading early-stage venture capital firms focused on transforming patient care

Open-Innovation Partnerships

We continue to establish strategic partnerships with leading pharmaceutical and biotechnology companies, as well as academic institutions to help allocate resources more efficiently, expand DIS™ applications and accelerate pipeline commercialization. All our collaborations are architected for speed and driven by our scientific strategy.